OpenAI announced on September 1, 2026 that ChatGPT for Healthcare now integrates directly with Epic's electronic health record system, which holds patient data for over 325 million people. Clinicians can now summarize charts, pull patient history, review lab results, and prepare for visits without leaving the patient record interface. The company also released a Healthcare Public Data plugin connecting to nine official sources—ClinicalTrials.gov, CMS Coverage, RxNorm, DailyMed, and PubMed among them. Individual U.S. users can install the plugin themselves, while enterprise administrators control deployment in their workspaces. The author cuts through the hype quickly: this isn't a technological breakthrough. It's a distribution play, and it's one that absorbs the entire pitch deck that thousands of healthtech startups have been selling for years. The real significance lies in what this move exposes about the healthtech industry. Distribution—not technology—was always the actual competitive advantage these companies claimed to have. OpenAI just swallowed the core value proposition of countless startups in a single press release. The author points to companies like OpenEvidence and UpToDate as examples where the moat was never the algorithm but rather access to physicians and clinical workflows. When a foundation model from OpenAI can plug into your EHR and pull data from regulated sources, specialized medical AI companies lose their primary selling point. The author emphasizes that survival in this space will require deep workflow integration, highly specialized medical data, regulated write-back capabilities, and willingness to own liability—not just a prompt wrapped around a retrieval-augmented generation system. The article challenges OpenAI's credibility claims, particularly a 99.1% safety number the company cited, dismissing it as marketing rather than peer-reviewed research. This distinction matters because healthcare requires genuine regulatory rigor, not promotional statistics. The piece ends by framing this moment as a reckoning for healthtech founders: they need to answer which companies actually survive when distribution barriers collapse. Some players like Abridge and Heidi face existential pressure. Others, like Epic's own Cosmos initiative, might consolidate power further. The question isn't whether AI can help clinicians—it obviously can—but who owns the relationship with the doctor and the patient record.